|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"cunningham d"
Showing items 1-25 of 28 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-12-01T02:29:13Z |
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
|
Cahn P.; Madero J.S.; Arribas J.R.; Antinori A.; Ortiz R.; Clarke A.E.; CHIEN-CHING HUNG; Rockstroh J.K.; Girard P.-M.; Sievers J.; Man C.; Currie A.; Underwood M.; Tenorio A.R.; Pappa K.; Wynne B.; Fettiplace A.; Gartland M.; Aboud M.; Smith K.; Cassetti L.; David D.; Figueras L.; Losso M.; Lopardo G.; Lupo S.; Porteiro N.; S?nchez M.; Bloch M.; Cooper D.; Finlayson R.; Kelleher A.; Koh K.; Lewis D.; McMahon J.; Moore R.; Roth N.; Shields M.; De Wit S.; Florence E.; Goffard J.-C.; Demeester R.; Lacor P.; Vandercam B.; Vandekerckhove L.; Angel J.; Baril J.-G.; Conway B.; De Pokomandy A.; Szabo J.; Walmsley S.; Bouchaud O.; Chidiac C.; Delobel P.; Goujard C.; Katlama C.; Molina J.-M.; Pialoux G.; Philibert P.; Bogner J.; Esser S.; Krznaric I.; Lehmann C.; Spinner C.; Stellbrink H.-J.; Stephan C.; Stoehr A.; Barchi E.; Caramello P.; Castelli F.; Cattelan A.M.; D'Arminio Monforte A.; Di Biagio A.; Di Perri G.; Gori A.; Maggiolo F.; Menzaghi B.; Migliorino G.; Mussini C.; Penco G.; Puoti M.; Rizzardini G.; Gulminetti R.; Lazzarin A.; Quirino T.; Sighinolfi L.; Viale P.; Amaya Tapia G.; Andrade Villanueva J.; Granados Reyes E.R.; Perez Rios A.; Santoscoy Gomez M.; Den Hollander J.; Rijnders B.; Hidalgo J.A.; Hercilla Vasquez L.; Illescas L.; Olczak A.; Mansinho K.; Correia Pacheco P.P.; Te?filo E.; Saraiva da Cunha J.; Sarmento e Castro R.; Serr?o R.; Arbune M.; Jianu C.; Oprea A.; Preotescu L.; Prisacariu L.-J.; Belonosova E.; Borodkina O.; Chernova O.; Gankina N.; Kizhlo S.; Kulagin V.; Kurina N.; Nagimova F.; Pokrovsky V.; Ryamova E.; Voronin E.; Yakovlev A.; Kaplan R.; Lee S.H.; Kim S.-W.; Kim S.-I.; Kim W.J.; Antela Lopez A.; Casado Osorio J.L.; Casta?o Carracedo M.A.; De Los Santos Gil I.; Estrada Perez V.; Falco Ferrer V.; Force L.; Galinda Puerto M.J.; Garcia Deltoro M.; Gatell J.M.; Goenaga Sanchez M.A.; Gonz?lez Cord?n A.; Knobel H.; Lopez Bernaldo de Quiros J.C.; Losa Garcia J.E.; Masia M.; Montero-Alsonso M.; Ocampo Hermida A.; Pasquau Lia?o J.; Portilla Sogorb J.; Pulido Ortega F.; Rivera Roman A.; Santos Fernandez J.R.; Torres Perea R.; Troya Garcia J.; Viciana Fernandez P.; Calmy A.; Hauser C.; Fehr J.; Cheng S.-H.; Ko W.-C.; Lin H.-H.; Lu P.-L.; Tseng Y.-T.; Wang N.-C.; Wong W.-W.; Yang C.-J.; Arduino R.; Benson P.; Berhe M.; Bredeek F.; Brinson C.; Campbell T.; Crofoot G.; Cunningham D.; DeJesus E.; Dretler R.; Eron J.; Fife K.; Fichtenbaum C.; Flamm J.; Goldstein D.; Gupta S.; Hagins D.; Hoffman-Terry M.; Jayaweera D.; Kinder C.; Klein D.; McDonald C.; Mills A.; Nahass R.; Osiyemi O.; Overton E.; Parks D.; Prelutsky D.; Ramgopal M.; Schrader S.; Sha B.; Simon G.; Sims J.; Skiest D.; Slim J.; Tashima K.; Thedinger B.; Gazzard B.; Fox J.; Johnson M.; Kegg S.; Khoo S.; Mazhude C.; Orkin C.; Schembri G.; Ustianowski A.; GEMINI Study Team |
| 臺大學術典藏 |
2021-05-03T02:20:50Z |
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
|
Wasan H.S.; Gibbs P.; Sharma N.K.; Taieb J.; Heinemann V.; Ricke J.; Peeters M.; Findlay M.; Weaver A.; Mills J.; Wilson C.; Adams R.; Francis A.; Moschandreas J.; Virdee P.S.; Dutton P.; Love S.; Gebski V.; Gray A.; Bateman A.; Blesing C.; Brown E.; Chau I.; Cummins S.; Cunningham D.; Falk S.; Hadaki M.; Hall M.; Hickish T.; Hornbuckle J.; Lofts F.; Lowndes S.; Mayer A.; Metcalfe M.; Middleton G.; Montazeri A.; Muirhead R.; Polychronis A.; Purcell C.; Ross P.; Sharma R.A.; Sherwin L.; Smith D.; Soomal R.; Swinson D.; Walther A.; Wilson G.; Amin P.; Angelelli B.; Balosso J.; Beny A.; Bloomgarden D.; Boucher E.; Bruch H.-R.; Bui J.; Burge M.; Cardaci G.; Carlisle J.; Chai S.; Chen Y.-J.; Chevallier P.; Chuong M.; Clarke S.; Coveler A.; Craninx M.; Delanoit T.; Deleporte A.; Eliadis P.; Facchini F.; Ferguson T.; Ferrante M.; Frenette G.; Frick J.; Ganju V.; Garofalo M.; Geboes K.; Gehbauer G.; George B.; Geva R.; Gordon M.; Gregory K.; Gulec S.; Hannigan J.; van Hazel G.; Heching N.; Helmberger T.; Hendlisz A.; Hendrickx K.; Holtzman M.; Isaacs R.; Jackson C.; James P.; Kaiser A.; Karapetis C.; Kaubisch A.; Ko Y.-D.; Kr?ning H.; Lammert F.; Liauw W.; Limentani S.; Louafi S.; de Man M.; Margolis J.; Martin R.; Martoni A.; Marx G.; Matos M.; Monsaert E.; Moons V.; Nott L.; Nusch A.; O'Donnell A.; Ozer H.; Padia S.; Pavlakis N.; Perez D.; Pluntke S.; Polus M.; Powell A.; Pracht M.; Price T.; Ransom D.; Rebischung C.; Ridwelski K.; Riera-Knorrenschild J.; Riess H.; Rilling W.; Robinson B.; Rodr?guez J.; Sanchez F.; Sauerbruch T.; Savin M.; Scheidhauer K.; Schneiderman E.; Seeger G.; Segelov E.; Schmueli E.S.; Shani A.; Shannon J.; Shibata S.; Singhal N.; Smith D.; Smith R.; Stemmer S.; St?tzer O.; Strickland A.; Tatsch K.; Terrebonne E.; Tichler T.; Vehling-Kaiser U.; Vera-Garcia R.; Vogl T.; Walpole E.; Wang E.; Whiting S.; Wolf I.; Ades S.; Aghmesheh M.; Auber M.; Ayala H.; Boland P.; Bouche E.; Bowers C.; Bremer C.; Casado A.R.; Cooray P.; Crain M.; De Wit M.; Dowling K.; Durand A.; Faivre S.; Feeney K.; Ferru A.; Fragoso M.; Granetto C.; Hammel P.; Issacs R.; Iyer R.; Kim Y.H.; JIN-TUNG LIANG; Lim L.; Liu J.H.; Masi G.; Mosconi S.; Numico G.; Ratner L.; Sae-Won H.; Singh M.; Stoltzfus P.; Tan I.; Trogu A.; Underhill C.; Westcott M.; FOXFIRE trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, SIRFLOX trial investigators, FOXFIRE-Global trial investigators, FOXFIRE-Global trial investigators |
| 臺大學術典藏 |
2021-05-03T02:20:41Z |
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
|
Andr? T.;Vernerey D.;Im S.A.;Bodoky G.;Buzzoni R.;Reingold S.;Rivera F.;Mckendrick J.;Scheithauer W.;Ravit G.;Fountzilas G.;Yong W.P.;Isaacs R.;?Sterlund P.;Jin-Tung Liang;Creemers G.J.;Rakez M.;Van Cutsem E.;Cunningham D.;Tabernero J.;De Gramont A.; Andr? T.; Vernerey D.; Im S.A.; Bodoky G.; Buzzoni R.; Reingold S.; Rivera F.; McKendrick J.; Scheithauer W.; Ravit G.; Fountzilas G.; Yong W.P.; Isaacs R.; ?sterlund P.; JIN-TUNG LIANG; Creemers G.J.; Rakez M.; Van Cutsem E.; Cunningham D.; Tabernero J.; de Gramont A. |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國立成功大學 |
2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
|
MacArulla, Mercad� T.;Chen, L.-T.;Li, C.-P.;Siveke, J.T.;Cunningham, D.;Bodoky, G.;Blanc, J.-F.;Lee, K.-H.;Dean, A.;Belanger, Belanger B.;Wang-Gillam, A. |
| 臺大學術典藏 |
2019 |
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
|
Slim J.; Tashima K.; Thedinger B.; Gazzard B.; Fox J.; Johnson M.; Kegg S.; Khoo S.; Mazhude C.; Orkin C.; Schembri G.; Ustianowski A.; GEMINI Study Team; Yang C.-J.; Arduino R.; Benson P.; Berhe M.; Bredeek F.; Brinson C.; Campbell T.; Crofoot G.; Cunningham D.; DeJesus E.; Dretler R.; Illescas L.; Hercilla Vasquez L.; Hidalgo J.A.; Rijnders B.; Amaya Tapia G.; Andrade Villanueva J.; Granados Reyes E.R.; Perez Rios A.; Santoscoy Gomez M.; Den Hollander J.; Viale P.; Di Biagio A.; Di Perri G.; Gori A.; Maggiolo F.; Menzaghi B.; Migliorino G.; Mussini C.; Penco G.; Puoti M.; Rizzardini G.; Gulminetti R.; Lazzarin A.; Quirino T.; Sighinolfi L.; Ryamova E.; Pokrovsky V.; Borodkina O.; Chernova O.; Gankina N.; Kizhlo S.; Kulagin V.; Kurina N.; Nagimova F.; Belonosova E.; Olczak A.; Mansinho K.; Correia Pacheco P.P.; Te?filo E.; Saraiva da Cunha J.; Sarmento e Castro R.; Serr?o R.; Arbune M.; Jianu C.; Oprea A.; Preotescu L.; Prisacariu L.-J.; Wong W.-W.; Wang N.-C.; Fehr J.; Cheng S.-H.; Ko W.-C.; Lin H.-H.; Lu P.-L.; Tseng Y.-T.; Hauser C.; Calmy A.; Montero-Alsonso M.; Ocampo Hermida A.; Pasquau Lia?o J.; Portilla Sogorb J.; Pulido Ortega F.; Rivera Roman A.; Santos Fernandez J.R.; Torres Perea R.; Troya Garcia J.; Viciana Fernandez P.; Voronin E.; Yakovlev A.; Kaplan R.; Lee S.H.; Kim S.-W.; Kim S.-I.; Kim W.J.; Antela Lopez A.; Casado Osorio J.L.; Casta?o Carracedo M.A.; De Los Santos Gil I.; Estrada Perez V.; Falco Ferrer V.; Force L.; Galinda Puerto M.J.; Garcia Deltoro M.; Gatell J.M.; Goenaga Sanchez M.A.; Gonz?lez Cord?n A.; Knobel H.; Lopez Bernaldo de Quiros J.C.; Losa Garcia J.E.; Masia M.; Skiest D.; Sims J.; Overton E.; Parks D.; Prelutsky D.; Ramgopal M.; Schrader S.; Sha B.; Simon G.; Osiyemi O.; Nahass R.; Eron J.; Fife K.; Fichtenbaum C.; Flamm J.; Goldstein D.; Gupta S.; Hagins D.; Hoffman-Terry M.; Jayaweera D.; Kinder C.; Klein D.; McDonald C.; Mills A.; Castelli F.; Cattelan A.M.; D'Arminio Monforte A.; Barchi E.; Caramello P.; Stoehr A.; Stephan C.; Stellbrink H.-J.; Spinner C.; Lehmann C.; Krznaric I.; Goujard C.; Katlama C.; Molina J.-M.; Pialoux G.; Philibert P.; Bogner J.; Esser S.; Delobel P.; Conway B.; De Pokomandy A.; Szabo J.; Walmsley S.; Bouchaud O.; Chidiac C.; Gartland M.; Aboud M.; Smith K.; Cassetti L.; David D.; Figueras L.; Losso M.; Lopardo G.; Lupo S.; Porteiro N.; S?nchez M.; Bloch M.; Cooper D.; Finlayson R.; Kelleher A.; Koh K.; Lewis D.; McMahon J.; Moore R.; Roth N.; Fettiplace A.; Wynne B.; Pappa K.; Underwood M.; Tenorio A.R.; Currie A.; Man C.; Sievers J.; Girard P.-M.; Cahn P.; Madero J.S.; Arribas J.R.; Antinori A.; Ortiz R.; Clarke A.E.; CHIEN-CHING HUNG; Rockstroh J.K.; Angel J.; Baril J.-G.; Vandekerckhove L.; Vandercam B.; Lacor P.; Goffard J.-C.; Demeester R.; Florence E.; De Wit S.; Shields M.; Cahn P.;Madero J.S.;Arribas J.R.;Antinori A.;Ortiz R.;Clarke A.E.;Chien-Ching Hung;Rockstroh J.K.;Girard P.-M.;Sievers J.;Man C.;Currie A.;Underwood M.;Tenorio A.R.;Pappa K.;Wynne B.;Fettiplace A.;Gartland M.;Aboud M.;Smith K.;Cassetti L.;David D.;Figueras L.;Losso M.;Lopardo G.;Lupo S.;Porteiro N.;S?Nchez M.;Bloch M.;Cooper D.;Finlayson R.;Kelleher A.;Koh K.;Lewis D.;Mcmahon J.;Moore R.;Roth N.;Shields M.;De Wit S.;Florence E.;Goffard J.-C.;Demeester R.;Lacor P.;Vandercam B.;Vandekerckhove L.;Angel J.;Baril J.-G.;Conway B.;De Pokomandy A.;Szabo J.;Walmsley S.;Bouchaud O.;Chidiac C.;Delobel P.;Goujard C.;Katlama C.;Molina J.-M.;Pialoux G.;Philibert P.;Bogner J.;Esser S.;Krznaric I.;Lehmann C.;Spinner C.;Stellbrink H.-J.;Stephan C.;Stoehr A.;Barchi E.;Caramello P.;Castelli F.;Cattelan A.M.;D'Arminio Monforte A.;Di Biagio A.;Di Perri G.;Gori A.;Maggiolo F.;Menzaghi B.;Migliorino G.;Mussini C.;Penco G.;Puoti M.;Rizzardini G.;Gulminetti R.;Lazzarin A.;Quirino T.;Sighinolfi L.;Viale P.;Amaya Tapia G.;Andrade Villanueva J.;Granados Reyes E.R.;Perez Rios A.;Santoscoy Gomez M.;Den Hollander J.;Rijnders B.;Hidalgo J.A.;Hercilla Vasquez L.;Illescas L.;Olczak A.;Mansinho K.;Correia Pacheco P.P.;Te?Filo E.;Saraiva Da Cunha J.;Sarmento E Castro R.;Serr?O R.;Arbune M.;Jianu C.;Oprea A.;Preotescu L.;Prisacariu L.-J.;Belonosova E.;Borodkina O.;Chernova O.;Gankina N.;Kizhlo S.;Kulagin V.;Kurina N.;Nagimova F.;Pokrovsky V.;Ryamova E.;Voronin E.;Yakovlev A.;Kaplan R.;Lee S.H.;Kim S.-W.;Kim S.-I.;Kim W.J.;Antela Lopez A.;Casado Osorio J.L.;Casta?O Carracedo M.A.;De Los Santos Gil I.;Estrada Perez V.;Falco Ferrer V.;Force L.;Galinda Puerto M.J.;Garcia Deltoro M.;Gatell J.M.;Goenaga Sanchez M.A.;Gonz?Lez Cord?N A.;Knobel H.;Lopez Bernaldo De Quiros J.C.;Losa Garcia J.E.;Masia M.;Montero-Alsonso M.;Ocampo Hermida A.;Pasquau Lia?O J.;Portilla Sogorb J.;Pulido Ortega F.;Rivera Roman A.;Santos Fernandez J.R.;Torres Perea R.;Troya Garcia J.;Viciana Fernandez P.;Calmy A.;Hauser C.;Fehr J.;Cheng S.-H.;Ko W.-C.;Lin H.-H.;Lu P.-L.;Tseng Y.-T.;Wang N.-C.;Wong W.-W.;Yang C.-J.;Arduino R.;Benson P.;Berhe M.;Bredeek F.;Brinson C.;Campbell T.;Crofoot G.;Cunningham D.;Dejesus E.;Dretler R.;Eron J.;Fife K.;Fichtenbaum C.;Flamm J.;Goldstein D.;Gupta S.;Hagins D.;Hoffman-Terry M.;Jayaweera D.;Kinder C.;Klein D.;Mcdonald C.;Mills A.;Nahass R.;Osiyemi O.;Overton E.;Parks D.;Prelutsky D.;Ramgopal M.;Schrader S.;Sha B.;Simon G.;Sims J.;Skiest D.;Slim J.;Tashima K.;Thedinger B.;Gazzard B.;Fox J.;Johnson M.;Kegg S.;Khoo S.;Mazhude C.;Orkin C.;Schembri G.;Ustianowski A.;Gemini Study Team |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan
|
Siveke, JT;Hubner, R;Macarulla, TM;Wang-Gillam, A;Dean, AP;Blanc, JF;Cunningham, D;Mirakhur, B;Belanger, B;de Jong, FA;Chen, LT |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g
|
Macarulla, TM;Hubner, R;Blanc, JF;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Yanshen, S;Jameson, GS;Lee, KH;Chiu, CF;Schwartsmann, G;Braiteh, FS;Cunningham, D;Chen, LT;Von Hoff, DD;Mamlouk, KK;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p
|
Macarulla, TM;Siveke, JT;Dean, AP;Hubner, R;Blanc, JF;Cunningham, D;Chen, LT;Mirakhur, B;Chen, J;de Jong, FA;Wang-Gillam, A |
| 國立成功大學 |
2018 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, L.-T.;Siveke, J.T.;Wang-Gillam, A.;Li, C.-P.;Bodoky, G.;Dean, A.P.;Shan, Y.-S.;Jameson, G.S.;Macarulla, T.;Lee, K.-H.;Cunningham, D.;Blanc, J.-F.;Chiu, Chiu C.-F.;Schwartsmann, G.;Braiteh, F.S.;Mamlouk, K.;Belanger, Belanger B.;de, Jong F.A.;Hubner, R.A. |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon
|
Hubner, RA;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Siveke, JT;Braiteh, FS;de Jong, FA;Belanger, B;Walls, R;Mody, PD;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM
|
Wang-Gillam, A;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, FA;Mody, PD;Von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2017-02 |
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Siveke, JT;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, F;Mody, PD;Chen, LT;Von Hoff, DD |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
| 國家衛生研究院 |
2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, JT;Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Braiteh, F;Moyo, V;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國立成功大學 |
2016 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, Jens T.;Chen, Li-Tzong;Von Hoff, Daniel D;Li, Chung-Pin;Wang-Gillam, Andrew;Bodoky, Gyorgy;Dean, Andrew;Shan, Yan-Shen;Jameson, Gayel S;Macarulla, T.;Lee, K-H;Cunningham, D.;Blanc, J-F;Hubner, R. A.;Chiu, C-F;Schwartsmann, G.;Braiteh, F.;Moyo, V.;Belanger, B.;Bayever, E. |
| 國家衛生研究院 |
2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2013-06-21 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
|
Roy, AC;Park, SR;Cunningham, D;Kang, YK;Chao, Y;Chen, LT;Rees, C;Lim, HY;Tabernero, J;Ramos, FJ;Kujundzic, M;Cardic, MB;Yeh, CG;De Gramont, A |
| 國立成功大學 |
2013-06 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
|
Roy, A. C.; Park, S. R.; Cunningham, D.; Kang, Y. K.; Chao, Y.; Chen, L. T.; Rees, C.; Lim, H. Y.; Tabernero, J.; Ramos, F. J.; Kujundzic, M.; Cardic, M. B.; Yeh, C. G.; de Gramont, A. |
Showing items 1-25 of 28 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
